Abstracts tagged "B-Cell Targets"

Abstract Number: 0947 • ACR Convergence 2020
STING Gain-of-Function in Radio-resistant Cells Supports a Lymphocyte Dependent Auto-inflammatory Lung Disease
Kevin Gao¹, Mona Motwani¹, Ann Marshak-Rothstein² and Katherine Fitzgerald¹, ¹University of Massachusetts medical school, worcester, MA, ²University of Massachusetts medical school, Newton, MA
Background/Purpose: cGAS-STING is a cytosolic dsDNA sensing pathway whose regulation is vital to immune homeostasis. Pediatric patients with constitutively active STING mutations develop an autoinflammatory…
Abstract Number: 0991 • ACR Convergence 2020
Pathogenic, Glycolytic PD-1+ B Cells Accumulate in the Hypoxic RA Joint
Achilleas Floudas¹, Nuno Neto², Viviana Marzaioli³, Kieran Murray⁴, Barry Moran⁵, Michael Monaghan⁶, Candice Low⁷, Ronan Mullan⁸, Navin Rao⁹, Vinod Krishna⁹, Sunil Nagpal¹⁰, Douglas Veale¹¹ and Ursula Fearon³, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, ²Department of Mechanical and Manufacturing Engineering, Dublin, Dublin, Ireland, ³Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ⁵Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁶Department of Mechanical and Manufacturing Engineering, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ⁸Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁹Janssen R&D, Spring House, PA, ¹⁰Janssen Research & Development, Collegeville, PA, ¹¹EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) often has a progressive and debilitating course, with significant impact on the patient’s quality of life. Despite the long-known association with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].